After elevating the value of COVID-19 vaccines greater than fourfold this yr, Pfizer CEO Albert Bourla advised buyers Monday that the corporate can even doubtless hike the value of its lifesaving COVID-19 antiviral remedy, Paxlovid, elevating additional concern about entry and well being care prices.
The worth of the drug is already $530 for a remedy course. That is what the US authorities paid for the drug within the emergency part of the pandemic. However, because the drug strikes from authorities distribution to the business market this yr, the value is predicted to extend. To this point, it is unclear what the brand new worth will likely be.
In an organization investor name Monday, Bourla mentioned solely that the “pandemic worth” of $530 is more likely to be “lesser” than the business worth and that negotiations are starting.
Learn 7 remaining paragraphs | Feedback